Literature DB >> 30174275

Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale.

Attila Makkos1, Márton Kovács1, Dávid Pintér2, József Janszky3, Norbert Kovács4.   

Abstract

BACKGROUND: Motor complications represent an important clinical problem in the treatment of Parkinson's disease (PD). The Motor Complications Part of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part IV) and the Unified Dyskinesia Rating Scale (UDysRS) are among the most reliable instruments to evaluate these problems. The minimal clinically important difference thresholds are the smallest changes in the outcome measures that are clinically meaningful. AIMS: The aim of our study was to calculate the minimal clinically important difference thresholds for the MDS-UPDRS Part IV and the historic parts of the UDysRS.
METHODS: A total of 1044 paired investigations of 436 patients were analyzed. Changes in the respective outcome measures (MDS-UPDRS Part IV, UDysRS Parts I and II) were compared to the Patient-rated Global Impression of Improvement scores (anchors). Subsequently, we applied receiver-operating characteristic analysis to ascertain the MCID thresholds with optimal sensitivity and specificity.
RESULTS: Any improvement greater than 2.1 points or any worsening greater than 1.8 points on UDysRS Part I represents a minimal, yet clinically meaningful change. In reference to UDysRS Part II, the smallest changes considered clinically relevant are 1.8 and 1.7 points for improvement and deterioration, respectively. The thresholds for the MDS-UPDRS Part IV are 0.9 points for improvement and 0.8 points for worsening.
CONCLUSIONS: Our estimates may allow the judgment of the clinical relevance of numeric changes in the dyskinesia scales.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Minimal but clinically relevant differences; Minimal clinically important changes; Parkinson disease; Receiver operating characteristic curve; Unified Dyskinesia Rating Scale

Mesh:

Substances:

Year:  2018        PMID: 30174275     DOI: 10.1016/j.parkreldis.2018.08.018

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  6 in total

1.  EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.

Authors:  Caroline M Tanner; Rajesh Pahwa; Robert A Hauser; Wolfgang H Oertel; Stuart H Isaacson; Joseph Jankovic; Reed Johnson; Dustin Chernick; Jean Hubble
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

2.  Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study.

Authors:  Haiyan Zhou; Shuhua Li; Hongmei Yu; Shenggang Sun; Xinhua Wan; Xiaodong Zhu; Chun-Feng Liu; Ling Chen; Wei Xiang; Yaqing Sun; Haibo Chen; Shengdi Chen
Journal:  Parkinsons Dis       Date:  2021-03-03

3.  DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.

Authors:  David G Standaert; Jason Aldred; Marieta Anca-Herschkovitsch; Paul Bourgeois; Esther Cubo; Thomas L Davis; Robert Iansek; Norbert Kovács; Francesco E Pontieri; Mustafa S Siddiqui; Mihaela Simu; Lars Bergmann; Pavnit Kukreja; Weining Z Robieson; K Ray Chaudhuri
Journal:  Mov Disord Clin Pract       Date:  2021-09-12

4.  Does Subthalamic Deep Brain Stimulation Impact Asymmetry and Dyscoordination of Gait in Parkinson's Disease?

Authors:  Deepak K Ravi; Christian R Baumann; Elena Bernasconi; Michelle Gwerder; Niklas K Ignasiak; Mechtild Uhl; Lennart Stieglitz; William R Taylor; Navrag B Singh
Journal:  Neurorehabil Neural Repair       Date:  2021-09-22       Impact factor: 3.919

5.  Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.

Authors:  Robert A Hauser; Judy Lytle; Andrea E Formella; Caroline M Tanner
Journal:  NPJ Parkinsons Dis       Date:  2022-03-18

6.  Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.

Authors:  Eric Freire-Alvarez; Egon Kurča; Lydia Lopez Manzanares; Eero Pekkonen; Cleanthe Spanaki; Paola Vanni; Yang Liu; Olga Sánchez-Soliño; Luigi M Barbato
Journal:  Mov Disord       Date:  2021-07-08       Impact factor: 9.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.